⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HURA News
TuHURA Biosciences, Inc. Common Stock
TuHURA Biosciences Provides Corporate Update Following Recent Financing
prnewswire.com
HURA
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
prnewswire.com
HURA
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
prnewswire.com
HURA
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
prnewswire.com
HURA
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
prnewswire.com
HURA